merged_novo-nordisk-earnings-ozempic-wegovy.txt
<question_number>1</question_number>
<answer>N/A</answer>

<question_number>2</question_number>
<answer>N/A</answer>

<question_number>3</question_number>
<answer>N/A</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>N/A</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>N/A</answer>

<question_number>8</question_number>
<answer>N/A</answer>

<question_number>9</question_number>
<answer>N/A</answer>

<question_number>10</question_number>
<answer>N/A</answer>

<question_number>11</question_number>
<answer>1 USD = 7.14 DKK</answer>

<other>The conversion rate can be calculated by dividing the revenue in Danish kroner by the revenue in U.S. dollars: 290 billion DKK / $40.6 billion = 7.14 DKK/USD.</other>

<question_number>12</question_number>
<answer>CagriSema</answer>

<question_number>13</question_number>
<answer>President Trump's election</answer>

<question_number>14</question_number>
<answer>Novo Nordisk</answer>

<other>Novo Nordisk is the Danish pharmaceutical company mentioned in the article, and Denmark is the country implicated by the geopolitical tensions due to the U.S. President's threat of tariffs.</other>

<question_number>15</question_number>
<answer>16</answer>

<question_number>16</question_number>
<answer>40</answer>

<question_number>17</question_number>
<answer>2</answer>

<other>The article explicitly names Ozempic and Wegovy as the obesity drugs produced by Novo Nordisk.</other>

<question_number>18</question_number>
<answer>United States</answer>

<question_number>19</question_number>
<answer>European Union</answer>

<question_number>20</question_number>
<answer>Geopolitics</answer>

<other>The CFO, Karsten Munk Knudsen, is quoted as saying "Geopolitics is probably more volatile currently as compared to what it's been in the past few years," indicating that geopolitics is the factor identified as increasingly volatile and potentially challenging the growth outlook.</other>